BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Non-Hodgkin Lymphoma readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Non-Hodgkin Lymphoma\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06287398-10986@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT06287398)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASC
 T & Epcor Consolidation in Patients With Relapsed LBCL\nEstimated primary 
 completion: November 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/epcoritamab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06287398
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02393157-2649@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT02393157)
DESCRIPTION:Obinutuzumab\, phase 2\, Follicular Lymphoma.\nStudy: Obinutuzu
 mab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL\nEstimat
 ed primary completion: December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT02393157
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04512534-2286@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Chidamide: Phase 2 readout est. (NCT04512534)
DESCRIPTION:Chidamide\, phase 2\, Peripheral T-Cell Lymphoma.\nStudy: Sinti
 limab Combined With Chidamide in Treating Peripheral T Cell Lymphoma\nEsti
 mated primary completion: 1 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/chidamide#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT04512534
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04077723-2649@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:Obinutuzumab: Phase 1/2 readout est. (NCT04077723)
DESCRIPTION:Obinutuzumab\, phase 1/2\, Non-Hodgkin Lymphoma.\nStudy: A Stud
 y to Evaluate the Safety\, Pharmacokinetics and Preliminary Anti-Tumor Act
 ivity of Englumafusp Alfa in Combination With Obinutuzumab and in Combinat
 ion With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Part
 icipants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma\nEstimated
  primary completion: 28 December 2026. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT04077723
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05958719-2286@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Chidamide: Phase 2 readout est. (NCT05958719)
DESCRIPTION:Chidamide\, phase 2\, Peripheral T-Cell Lymphoma.\nStudy: Chida
 mide in Combination With Azacitidine\, Liposomal Mitoxantrone\, and Predni
 sone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Ce
 ll Lymphoma\nEstimated primary completion: 30 December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/chidamide#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05958719
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06151106-2286@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Chidamide: Phase 2 readout est. (NCT06151106)
DESCRIPTION:Chidamide\, phase 2\, Peripheral T-Cell Lymphoma.\nStudy: Chida
 mide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T
 -cell Lymphoma\nEstimated primary completion: 31 December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/chidamide#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06151106
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06760156-5647@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT06760156)
DESCRIPTION:Tafasitamab\, phase 2\, Large B-Cell Lymphoma.\nStudy: Tafasita
 mab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Ly
 m\nEstimated primary completion: January 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/tafasitamab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06760156
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04978584-5647@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270116
DTEND;VALUE=DATE:20270117
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT04978584)
DESCRIPTION:Tafasitamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Rituximab\, Lenalidomide\, Acalabrutinib\, Tafasitamab Alone and With Comb
 ination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Cen
 ter Diffuse Large B-Cell Lymphoma\, Smart Stop Study\nEstimated primary co
 mpletion: 16 January 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/tafasitamab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT04978584
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06723457-10986@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270218
DTEND;VALUE=DATE:20270219
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT06723457)
DESCRIPTION:Epcoritamab\, phase 2\, Large B-Cell Lymphoma.\nStudy: Epcorita
 mab and Lenalidomide in Treating Patients With Refractory or Relapsed Immu
 nodeficiency-Related Large B-Cell Lymphoma\nEstimated primary completion: 
 18 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/epc
 oritamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06723457
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03995147-1973@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270220
DTEND;VALUE=DATE:20270221
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03995147)
DESCRIPTION:Pembrolizumab\, phase 2\, Large B-Cell Lymphoma.\nStudy: Pembro
 lizumab in Combination With Chemotherapy for Patients With Untreated B Cel
 l Lymphoma\nEstimated primary completion: 20 February 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT03995147
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06519526-2727@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Zeprumetostat: Phase 2 readout est. (NCT06519526)
DESCRIPTION:Zeprumetostat\, phase 2\, Peripheral T-Cell Lymphoma.\nStudy: E
 xploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relaps
 ed/Refractory Peripheral T Cell Lymphoma\nEstimated primary completion: 28
  February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zepru
 metostat#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06519526
URL:https://assetmemo.bio/drug/zeprumetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05451810-10986@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT05451810)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Admini
 stered in the Outpatient Setting in Adult Participants With Relapsed or Re
 fractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma\nEs
 timated primary completion: March 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/epcoritamab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05451810
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06271057-11182@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Golcadomide: Phase 2 readout est. (NCT06271057)
DESCRIPTION:Golcadomide\, phase 2\, Large B-Cell Lymphoma.\nStudy: Golcadom
 ide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With 
 High Risk of Relapse\nEstimated primary completion: 31 March 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/golcadomide#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06271057
URL:https://assetmemo.bio/drug/golcadomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03930953-2649@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270407
DTEND;VALUE=DATE:20270408
SUMMARY:Obinutuzumab: Phase 1/2 readout est. (NCT03930953)
DESCRIPTION:Obinutuzumab\, phase 1/2\, Non-Hodgkin Lymphoma.\nStudy: A Safe
 ty and Preliminary Efficacy Study of CC-99282\, Alone and in Combination W
 ith Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-H
 odgkin Lymphomas (R/R NHL)\nEstimated primary completion: 7 April 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT03930953
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06421948-2286@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Chidamide: Phase 1/2 readout est. (NCT06421948)
DESCRIPTION:Chidamide\, phase 1/2\, Peripheral T-Cell Lymphoma.\nStudy: Lin
 perlisib Combined With Chidamide in Patients With PTCL\nEstimated primary 
 completion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/chidamide#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06421948
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05833724-2286@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Chidamide: Phase 2 readout est. (NCT05833724)
DESCRIPTION:Chidamide\, phase 2\, Peripheral T-Cell Lymphoma.\nStudy: Chida
 mide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R
 /R PTCL)\nEstimated primary completion: June 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/chidamide#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05833724
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05578976-10986@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Epcoritamab: Phase 3 readout est. (NCT05578976)
DESCRIPTION:Epcoritamab\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcori
 tamab Combined With Intravenous and Oral Rituximab\, Cyclophosphamide\, Do
 xorubicin Hydrochloride\, Vincristine\, and Prednisone (R-CHOP) or R-CHOP 
 in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (
 DLBCL)\nEstimated primary completion: June 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/epcoritamab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05578976
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05934448-1973@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270606
DTEND;VALUE=DATE:20270607
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05934448)
DESCRIPTION:Pembrolizumab\, phase 2\, Large B-Cell Lymphoma.\nStudy: Pembro
  Plus CAR T-cell Therapy in R/R in PMBCL\nEstimated primary completion: 6 
 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05934448
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06834373-11182@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270610
DTEND;VALUE=DATE:20270611
SUMMARY:Golcadomide: Phase 2 readout est. (NCT06834373)
DESCRIPTION:Golcadomide\, phase 2\, Large B-Cell Lymphoma.\nStudy: Golcadom
 ide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressiv
 e B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy\nEstimated primary
  completion: 10 June 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/golcadomide#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06834373
URL:https://assetmemo.bio/drug/golcadomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07917832-11182@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Golcadomide: Phase 2 readout est. (NCT07917832)
DESCRIPTION:Golcadomide\, phase 2\, Large B-Cell Lymphoma.\nStudy: Smart 3:
  A Multi-Center Phase 2 Trial Of Golcadomide\, Glofitamab And Polatuzumab 
 Vedotin (G2P) For Patients With Newly Diagnosed Large B-Cell Lymphoma\nEst
 imated primary completion: 30 June 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/golcadomide#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07917832
URL:https://assetmemo.bio/drug/golcadomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03328078-2947@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Emavusertib: Phase 1/2 readout est. (NCT03328078)
DESCRIPTION:Emavusertib\, phase 1/2\, Primary Central Nervous System Lympho
 ma.\nStudy: CA-4948-101: Open-Label\, Dose Escalation and Expansion Trial 
 of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous
  System Lymphoma (R/R PCNSL)\nEstimated primary completion: July 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/emavusertib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT03328078
URL:https://assetmemo.bio/drug/emavusertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05507541-1973@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05507541)
DESCRIPTION:Pembrolizumab\, phase 2\, Large B-Cell Lymphoma.\nStudy: TTI-62
 2 in Combination With Pembrolizumab for the Treatment of Relapsed or Refra
 ctory Diffuse Large B-Cell Lymphoma\nEstimated primary completion: 30 July
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0550
 7541
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07093710-2286@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Chidamide: Phase 1/2 readout est. (NCT07093710)
DESCRIPTION:Chidamide\, phase 1/2\, Peripheral T-Cell Lymphoma.\nStudy: Gol
 idocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide 
 in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma\nEst
 imated primary completion: 1 August 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/chidamide#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07093710
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04745949-2202@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270803
DTEND;VALUE=DATE:20270804
SUMMARY:Brentuximab Vedotin: Phase 2 readout est. (NCT04745949)
DESCRIPTION:Brentuximab Vedotin\, phase 2\, Large B-Cell Lymphoma.\nStudy: 
 PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody T
 herapy\, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy\nEstima
 ted primary completion: 3 August 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/brentuximab-vedotin#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04745949
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06356129-11182@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270809
DTEND;VALUE=DATE:20270810
SUMMARY:Golcadomide: Phase 3 readout est. (NCT06356129)
DESCRIPTION:Golcadomide\, phase 3\, Large B-Cell Lymphoma.\nStudy: Study to
  Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placeb
 o Plus R-CHOP in Participants With Previously Untreated High-risk Large B-
 cell Lymphoma\nEstimated primary completion: 9 August 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/golcadomide#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06356129
URL:https://assetmemo.bio/drug/golcadomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03223610-2649@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270812
DTEND;VALUE=DATE:20270813
SUMMARY:Obinutuzumab: Phase 1/2 readout est. (NCT03223610)
DESCRIPTION:Obinutuzumab\, phase 1/2\, Non-Hodgkin Lymphoma.\nStudy: Veneto
 clax\, Ibrutinib\, Prednisone\, Obinutuzumab\, and Revlimid (ViPOR) in Rel
 apsed/Refractory B-cell Lymphoma\nEstimated primary completion: 12 August 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT032236
 10
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06536049-10986@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Epcoritamab: Phase 1/2 readout est. (NCT06536049)
DESCRIPTION:Epcoritamab\, phase 1/2\, Diffuse Large B-Cell Lymphoma.\nStudy
 : Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory A
 ggressive B-Cell Non-Hodgkin Lymphoma\nEstimated primary completion: 31 Au
 gust 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcoritama
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 536049
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04542824-10986@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Epcoritamab: Phase 1/2 readout est. (NCT04542824)
DESCRIPTION:Epcoritamab\, phase 1/2\, Diffuse Large B-Cell Lymphoma.\nStudy
 : Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects Wit
 h Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)\nEs
 timated primary completion: September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/epcoritamab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04542824
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07451652-10986@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT07451652)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Low Dose Epcoritamab Plus GemOx in R/R DLBCL\nEstimated primary completion
 : September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/epc
 oritamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07451652
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07139353-2286@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Chidamide: Phase 1/2 readout est. (NCT07139353)
DESCRIPTION:Chidamide\, phase 1/2\, Peripheral T-Cell Lymphoma.\nStudy: Lin
 perlisib Combined With Chidamide in the Treatment of Relapsed or Refractor
 y Peripheral T-cell Lymphoma\nEstimated primary completion: 1 September 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/chidamide#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07139353
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04663347-10986@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Epcoritamab: Phase 1/2 readout est. (NCT04663347)
DESCRIPTION:Epcoritamab\, phase 1/2\, Diffuse Large B-Cell Lymphoma.\nStudy
 : Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B
 -cell Non-Hodgkin Lymphoma (B-NHL)\nEstimated primary completion: 30 Septe
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcoritama
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 663347
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06458439-10986@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT06458439)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Epcoritamab-CAR T Cells for Large B-cell Lymphomas\nEstimated primary comp
 letion: October 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /epcoritamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06458439
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06090539-2649@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:Obinutuzumab: Phase 1/2 readout est. (NCT06090539)
DESCRIPTION:Obinutuzumab\, phase 1/2\, Non-Hodgkin Lymphoma.\nStudy: A Stud
 y to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents 
 in Relapsed/Refractory Non-Hodgkin Lymphomas\nEstimated primary completion
 : 28 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ob
 inutuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06090539
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06561048-1499@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:soquelitinib: Phase 3 readout est. (NCT06561048)
DESCRIPTION:soquelitinib\, phase 3\, Peripheral T-Cell Lymphoma.\nStudy: So
 quelitinib vs Standard of Care in Participants With Relapsed/Refractory Pe
 ripheral T-cell Lymphoma Not Otherwise Specified\, Follicular Helper T-cel
 l Lymphomas\, or Systemic Anaplastic Large-cell Lymphoma\nEstimated primar
 y completion: November 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/soquelitinib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06561048
URL:https://assetmemo.bio/drug/soquelitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05852717-10986@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20271124
DTEND;VALUE=DATE:20271125
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT05852717)
DESCRIPTION:Epcoritamab\, phase 2\, Large B-Cell Lymphoma.\nStudy: Safety a
 nd Efficacy of Epcoritamab With Gemcitabine\, Dexamethasone\, and Cisplati
 n (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma\
 nEstimated primary completion: 24 November 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/epcoritamab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05852717
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06500273-10855@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:cemacabtagene ansegedleucel: Phase 2 readout est. (NCT06500273)
DESCRIPTION:cemacabtagene ansegedleucel\, phase 2\, Large B-Cell Lymphoma.\
 nStudy: Consolidation of First-Line MRD+ Remission With Cema-cel in Patien
 ts With LBCL\nEstimated primary completion: December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/cemacabtagene-ansegedleucel#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06500273
URL:https://assetmemo.bio/drug/cemacabtagene-ansegedleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07269639-11182@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Golcadomide: Phase 1/2 readout est. (NCT07269639)
DESCRIPTION:Golcadomide\, phase 1/2\, Large B-Cell Lymphoma.\nStudy: Golcad
 omide\, Poseltinib\, and Rituximab for Relapsed/Refractory Diffuse Large B
 -cell Lymphoma\nEstimated primary completion: 1 December 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/golcadomide#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07269639
URL:https://assetmemo.bio/drug/golcadomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05678933-2286@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Chidamide: Phase 3 readout est. (NCT05678933)
DESCRIPTION:Chidamide\, phase 3\, Peripheral T-Cell Lymphoma.\nStudy: AC-CH
 OP Versus CHOP in Patients With Previously Untreated PTCL-TFH\nEstimated p
 rimary completion: 1 December 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/chidamide#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05678933
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06550336-2286@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Chidamide: Phase 2 readout est. (NCT06550336)
DESCRIPTION:Chidamide\, phase 2\, Peripheral T-Cell Lymphoma.\nStudy: A Cli
 nical Study Assessing the Efficacy of Chidamide for CD30-positive Peripher
 al T-cell Lymphoma (PTCL).\nEstimated primary completion: 30 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/chidamide#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06550336
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07706959-2286@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Chidamide: Phase 1/2 readout est. (NCT07706959)
DESCRIPTION:Chidamide\, phase 1/2\, Peripheral T-Cell Lymphoma.\nStudy: New
  Genotype-guided Treatment in Newly Diagnosed PTCL\nEstimated primary comp
 letion: January 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /chidamide#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07706959
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07706959-2727@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Zeprumetostat: Phase 1/2 readout est. (NCT07706959)
DESCRIPTION:Zeprumetostat\, phase 1/2\, Peripheral T-Cell Lymphoma.\nStudy:
  New Genotype-guided Treatment in Newly Diagnosed PTCL\nEstimated primary 
 completion: January 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/zeprumetostat#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07706959
URL:https://assetmemo.bio/drug/zeprumetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06931652-10986@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT06931652)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the C
 NS Treated With Lenalidomide and Rituximab\nEstimated primary completion: 
 January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcorit
 amab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06931652
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06508658-10986@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Epcoritamab: Phase 3 readout est. (NCT06508658)
DESCRIPTION:Epcoritamab\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tabl
 ets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemci
 tabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or R
 efractory Diffuse Large B-Cell Lymphoma\nEstimated primary completion: Mar
 ch 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0650
 8658
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06784726-5820@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20280410
DTEND;VALUE=DATE:20280411
SUMMARY:Odronextamab: Phase 2 readout est. (NCT06784726)
DESCRIPTION:Odronextamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy:
  Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CA
 R-T\nEstimated primary completion: 10 April 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/odronextamab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06784726
URL:https://assetmemo.bio/drug/odronextamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06526793-5561@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20280421
DTEND;VALUE=DATE:20280422
SUMMARY:Surovatamig: Phase 2 readout est. (NCT06526793)
DESCRIPTION:Surovatamig\, phase 2\, Follicular Lymphoma.\nStudy: Surovatami
 g (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) 
 B-cell NHL\nEstimated primary completion: 21 April 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/surovatamig#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06526793
URL:https://assetmemo.bio/drug/surovatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06230224-5820@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20280529
DTEND;VALUE=DATE:20280530
SUMMARY:Odronextamab: Phase 3 readout est. (NCT06230224)
DESCRIPTION:Odronextamab\, phase 3\, B-Cell Non-Hodgkin Lymphoma.\nStudy: A
  Trial to Learn How Effective and Safe Odronextamab is Compared to Standar
 d of Care for Adult Participants With Previously Treated Aggressive B-cell
  Non-Hodgkin Lymphoma\nEstimated primary completion: 29 May 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/odronextamab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06230224
URL:https://assetmemo.bio/drug/odronextamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07814001-10986@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT07814001)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma
  After Second-Line CAR T-cell Therapy\nEstimated primary completion: July 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0781400
 1
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06905509-10986@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT06905509)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologo
 us Hematopoietic Cell Transplant for the Treatment of Relapsed or Refracto
 ry Large B-cell Lymphoma\nEstimated primary completion: 1 July 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06905509
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07123454-5561@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20280704
DTEND;VALUE=DATE:20280705
SUMMARY:Surovatamig: Phase 1/2 readout est. (NCT07123454)
DESCRIPTION:Surovatamig\, phase 1/2\, B-Cell Non-Hodgkin Lymphoma.\nStudy: 
 A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticance
 r Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymph
 oma\nEstimated primary completion: 4 July 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/surovatamig#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07123454
URL:https://assetmemo.bio/drug/surovatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07123454-11147@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20280704
DTEND;VALUE=DATE:20280705
SUMMARY:AZD4512: Phase 1/2 readout est. (NCT07123454)
DESCRIPTION:AZD4512\, phase 1/2\, B-Cell Non-Hodgkin Lymphoma.\nStudy: A Ph
 ase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Ag
 ents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma\
 nEstimated primary completion: 4 July 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/azd4512#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07123454
URL:https://assetmemo.bio/drug/azd4512#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07746245-2286@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Chidamide: Phase 2 readout est. (NCT07746245)
DESCRIPTION:Chidamide\, phase 2\, Peripheral T-Cell Lymphoma.\nStudy: The E
 fficacy of CAPCT in Patients With PTCL\nEstimated primary completion: 31 J
 uly 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/chidamide#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07746
 245
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06045247-10986@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT06045247)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Ol
 der Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With N
 ewly Diagnosed Diffuse Large B-cell Lymphoma\nEstimated primary completion
 : 31 July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcor
 itamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06045247
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07725705-2727@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Zeprumetostat: Phase 1/2 readout est. (NCT07725705)
DESCRIPTION:Zeprumetostat\, phase 1/2\, Peripheral T-Cell Lymphoma.\nStudy:
  SHR2554 Plus Liposomal Mitoxantrone as First-line Treatment for Periphera
 l T-cell Lymphoma (PTCL)\nEstimated primary completion: 1 August 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/zeprumetostat#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07725705
URL:https://assetmemo.bio/drug/zeprumetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07588698-10986@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT07588698)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Ho
 dgkin Lymphoma\nEstimated primary completion: 31 August 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/epcoritamab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07588698
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06521255-5647@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Tafasitamab: Phase 3 readout est. (NCT06521255)
DESCRIPTION:Tafasitamab\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combin
 ation With Gemcitabine and Oxaliplatin Versus Rituximab in Combination Wit
 h Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse
  Large B-Cell Lymphoma\nEstimated primary completion: September 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tafasitamab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06521255
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07883135-2649@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07883135)
DESCRIPTION:Obinutuzumab\, phase 2\, Non-Hodgkin Lymphoma.\nStudy: Bispecif
 ic Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Ce
 ll Lymphomas\nEstimated primary completion: 1 October 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07883135
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07258680-2202@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Brentuximab Vedotin: Phase 3 readout est. (NCT07258680)
DESCRIPTION:Brentuximab Vedotin\, phase 3\, Peripheral T-Cell Lymphoma.\nSt
 udy: BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimi
 zing First-line Therapy of T-cell Lymphomas\nEstimated primary completion:
  December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/brent
 uximab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07258680
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07938619-5647@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT07938619)
DESCRIPTION:Tafasitamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Tafasitamab\, Lenalidomide\, Rituximab\, and Orelabrutinib for Patients Wi
 th Relapsed or Refractory Diffuse Large B-Cell Lymphoma\nEstimated primary
  completion: 1 December 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/tafasitamab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07938619
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06757387-2286@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Chidamide: Phase 1/2 readout est. (NCT06757387)
DESCRIPTION:Chidamide\, phase 1/2\, Peripheral T-Cell Lymphoma.\nStudy: Chi
 damide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphom
 a\nEstimated primary completion: 30 December 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/chidamide#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06757387
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06925555-2202@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Brentuximab Vedotin: Phase 2 readout est. (NCT06925555)
DESCRIPTION:Brentuximab Vedotin\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DL
 BCL-NOS\nEstimated primary completion: 30 December 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06925555
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05826535-10894@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Rondecabtagene autoleucel: Phase 1/2 readout est. (NCT05826535)
DESCRIPTION:Rondecabtagene autoleucel\, phase 1/2\, Large B-Cell Lymphoma.\
 nStudy: Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymp
 homa\nEstimated primary completion: 31 December 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/rondecabtagene-autoleucel#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05826535
URL:https://assetmemo.bio/drug/rondecabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07621406-5647@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT07621406)
DESCRIPTION:Tafasitamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Efficacy and Safety of Sequential Autologous Hematopoietic Stem Cell Trans
 plantation Combined With Tafasitamab\, Lenalidomide\, and Standard Immunoc
 hemotherapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma\nEstimat
 ed primary completion: 31 December 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/tafasitamab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07621406
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03625037-10986@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Epcoritamab: Phase 1/2 readout est. (NCT03625037)
DESCRIPTION:Epcoritamab\, phase 1/2\, Large B-Cell Lymphoma.\nStudy: First-
 in-Human (FIH) Trial in Patients With Relapsed\, Progressive or Refractory
  B-Cell Lymphoma\nEstimated primary completion: January 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/epcoritamab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT03625037
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04416984-10855@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:cemacabtagene ansegedleucel: Phase 1/2 readout est. (NCT04416984)
DESCRIPTION:cemacabtagene ansegedleucel\, phase 1/2\, Large B-Cell Lymphoma
 .\nStudy: Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cell
 s in Adults With Relapsed/Refractory Large B Cell Lymphoma\, Chronic Lymph
 ocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)\nEstimated primary
  completion: February 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/cemacabtagene-ansegedleucel#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04416984
URL:https://assetmemo.bio/drug/cemacabtagene-ansegedleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07347288-2727@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Zeprumetostat: Phase 2 readout est. (NCT07347288)
DESCRIPTION:Zeprumetostat\, phase 2\, Peripheral T-Cell Lymphoma.\nStudy: S
 HR2554 as Maintenance Therapy in Patients With Peripheral T-cell Lymphoma\
 nEstimated primary completion: February 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/zeprumetostat#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07347288
URL:https://assetmemo.bio/drug/zeprumetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03075696-2649@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20290330
DTEND;VALUE=DATE:20290331
SUMMARY:Obinutuzumab: Phase 1/2 readout est. (NCT03075696)
DESCRIPTION:Obinutuzumab\, phase 1/2\, Non-Hodgkin Lymphoma.\nStudy: A Dose
  Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combi
 nation With Obinutuzumab\, Administered After a Fixed\, Single Pre-treatme
 nt Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell No
 n-hodgkin's Lymphoma\nEstimated primary completion: 30 March 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT03075696
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06863402-1973@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06863402)
DESCRIPTION:Pembrolizumab\, phase 2\, Large B-Cell Lymphoma.\nStudy: Nemtab
 rutinib and Pembrolizumab for the Treatment of Richter Transformation\, Di
 ffuse Large B-cell Lymphoma Subtype\nEstimated primary completion: 1 June 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06863
 402
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07365306-10986@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20291015
DTEND;VALUE=DATE:20291016
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT07365306)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Epcoritamab\, Rituximab\, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage
  Therapy Before Autologous Stem Cell Transplant for the Treatment of Relap
 sed/Refractory Diffuse Large B-Cell Lymphoma\nEstimated primary completion
 : 15 October 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ep
 coritamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07365306
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07887750-5820@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20291101
DTEND;VALUE=DATE:20291102
SUMMARY:Odronextamab: Phase 1/2 readout est. (NCT07887750)
DESCRIPTION:Odronextamab\, phase 1/2\, Diffuse Large B-Cell Lymphoma.\nStud
 y: REGN9220 in Combination With Odronextamab in Adult Participants With Re
 lapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)\nEst
 imated primary completion: 1 November 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/odronextamab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07887750
URL:https://assetmemo.bio/drug/odronextamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05533775-2649@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Obinutuzumab: Phase 1/2 readout est. (NCT05533775)
DESCRIPTION:Obinutuzumab\, phase 1/2\, Non-Hodgkin Lymphoma.\nStudy: A Stud
 y to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy i
 n Pediatric and Young Adult Participants With Relapsed/Refractory Mature B
 -Cell Non-Hodgkin Lymphoma\nEstimated primary completion: 30 November 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05533775
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07188558-10894@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Rondecabtagene autoleucel: Phase 3 readout est. (NCT07188558)
DESCRIPTION:Rondecabtagene autoleucel\, phase 3\, Large B-Cell Lymphoma.\nS
 tudy: A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 C
 AR T-Cell Therapy\nEstimated primary completion: December 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/rondecabtagene-autoleucel#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07188558
URL:https://assetmemo.bio/drug/rondecabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05890352-5647@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT05890352)
DESCRIPTION:Tafasitamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Retur
 ned or Did Not Respond to Treatment\nEstimated primary completion: 1 Decem
 ber 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tafasitamab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT058
 90352
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06238648-10986@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT06238648)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients 
 Not in Complete Remission After CD19-directed CAR-T Therapy\nEstimated pri
 mary completion: 31 December 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/epcoritamab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06238648
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07502872-5647@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT07502872)
DESCRIPTION:Tafasitamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 TPG: Tafasitamab\, Polatuzumab Vedotin\, and Glofitamab as First-line Ther
 apy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma\nEsti
 mated primary completion: 1 January 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/tafasitamab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07502872
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07197307-10986@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT07197307)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Di
 ffuse Large B-cell Lymphoma (DLBCL)\nEstimated primary completion: 30 Apri
 l 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07197
 307
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06564038-5561@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20300520
DTEND;VALUE=DATE:20300521
SUMMARY:Surovatamig: Phase 1/2 readout est. (NCT06564038)
DESCRIPTION:Surovatamig\, phase 1/2\, Large B-Cell Lymphoma.\nStudy: A Stud
 y of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents f
 or Mature B-Cell Malignancies\nEstimated primary completion: 20 May 2030. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/surovatamig#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06564038
URL:https://assetmemo.bio/drug/surovatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07615283-2727@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20300529
DTEND;VALUE=DATE:20300530
SUMMARY:Zeprumetostat: Phase 1/2 readout est. (NCT07615283)
DESCRIPTION:Zeprumetostat\, phase 1/2\, Peripheral T-Cell Lymphoma.\nStudy:
  Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Ce
 ll Lymphoma\nEstimated primary completion: 29 May 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/zeprumetostat#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07615283
URL:https://assetmemo.bio/drug/zeprumetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07097363-10986@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT07097363)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Epcoritamab With Dose Adjusted Etoposide\, Cyclophosphamide\, Vincristine\
 , Doxorubicin\, Prednisone and Rituximab (EPOCH-R) for the Treatment of Ag
 gressive B-Cell Non-Hodgkin Lymphoma\nEstimated primary completion: 31 May
  2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070973
 63
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07215585-5561@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20300610
DTEND;VALUE=DATE:20300611
SUMMARY:Surovatamig: Phase 3 readout est. (NCT07215585)
DESCRIPTION:Surovatamig\, phase 3\, Large B-Cell Lymphoma.\nStudy: AZD0486 
 1L Therapy for Elderly or Unfit Participants With LBCL\nEstimated primary 
 completion: 10 June 2030. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/surovatamig#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07215585
URL:https://assetmemo.bio/drug/surovatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06072131-3412@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Belinostat: Phase 3 readout est. (NCT06072131)
DESCRIPTION:Belinostat\, phase 3\, Peripheral T-Cell Lymphoma.\nStudy: To E
 valuate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP
  Alone in PTCL\nEstimated primary completion: July 2030. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/belinostat#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06072131
URL:https://assetmemo.bio/drug/belinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07911553-5561@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20300902
DTEND;VALUE=DATE:20300903
SUMMARY:Surovatamig: Phase 3 readout est. (NCT07911553)
DESCRIPTION:Surovatamig\, phase 3\, Large B-Cell Lymphoma.\nStudy: A Study 
 to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80
  Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Sco
 re 2 to 5\nEstimated primary completion: 2 September 2030. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/surovatamig#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07911553
URL:https://assetmemo.bio/drug/surovatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06919939-10986@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20310107
DTEND;VALUE=DATE:20310108
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT06919939)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refract
 ory Large B-cell Lymphoma\nEstimated primary completion: 7 January 2031. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06919939
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05991388-5820@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20310501
DTEND;VALUE=DATE:20310502
SUMMARY:Odronextamab: Phase 2/3 readout est. (NCT05991388)
DESCRIPTION:Odronextamab\, phase 2/3\, B-Cell Non-Hodgkin Lymphoma.\nStudy:
  A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and 
 Refractory B-cell Non-Hodgkin Lymphoma\nEstimated primary completion: 1 Ma
 y 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/odronextamab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0599
 1388
URL:https://assetmemo.bio/drug/odronextamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07126236-5647@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20311227
DTEND;VALUE=DATE:20311228
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT07126236)
DESCRIPTION:Tafasitamab\, phase 2\, Large B-Cell Lymphoma.\nStudy: Response
 -adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy 
 of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma\n
 Estimated primary completion: 27 December 2031. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/tafasitamab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07126236
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07126236-10986@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20311227
DTEND;VALUE=DATE:20311228
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT07126236)
DESCRIPTION:Epcoritamab\, phase 2\, Large B-Cell Lymphoma.\nStudy: Response
 -adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy 
 of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma\n
 Estimated primary completion: 27 December 2031. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/epcoritamab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07126236
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06947967-2286@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Chidamide: Phase 3 readout est. (NCT06947967)
DESCRIPTION:Chidamide\, phase 3\, Peripheral T-Cell Lymphoma.\nStudy: Tucid
 inostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymp
 homa With Follicular Helper of T Cell Phenotype\nEstimated primary complet
 ion: December 2032. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/c
 hidamide#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06947967
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
